Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Central Government To Allocate RMB 2.7 Billion For Health Care Facilities In Rural Areas

This article was originally published in PharmAsia News

Executive Summary

The Ministry of Heath has revealed details for 2009's centralized purchasing of medical devices. The central government's almost RMB 2.7 billion funds ($392.9 million) for rural health care infrastructure on the level of county, village and hamlet will mainly be used for medical facilities and equipment. Besides continuing to provide basic health infrastructure for towns, the government will equip women's and children's health care organizations as well as TCM hospitals in the county. According to the "Program for Establishing and Developing a Rural Health Care Service System," the government will allocate an average of RMB 80,000 for general clinics, RMB 20,000 for central clinics, RMB 25,000 and RMB 380,000 for women's and children's health care centers and institutions respectively, and RMB 1 million for TCM hospitals. (Click here for more - Chinese Language)

You may also be interested in...



Increased Competition For Medical Devices Drives Profits Down For Shanghai Medical

SHANGHAI - Increased competition and pricing pressures for medical devices led to lower profits for Shanghai Medical Technology's second quarter ended June 30, the company announced Aug. 21

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel